Trial · NCT02528188
Adverse events351
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 351
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nasopharyngitis | Infections and infestations | Tanezumab 2.5 mg | 57 | 1,002 | |
| other | Nasopharyngitis | Infections and infestations | Tanezumab 5 mg | 67 | 998 | |
| other | Nasopharyngitis | Infections and infestations | NSAID | 40 | 996 | |
| other | Upper respiratory tract infection | Infections and infestations | Tanezumab 2.5 mg | 57 | 1,002 | |
| other | Upper respiratory tract infection | Infections and infestations | Tanezumab 5 mg | 45 | 998 | |
| other | Upper respiratory tract infection | Infections and infestations | NSAID | 59 | 996 | |
| other | Fall | Injury, poisoning and procedural complications | Tanezumab 2.5 mg | 65 | 1,002 | |
| other | Fall | Injury, poisoning and procedural complications | Tanezumab 5 mg | 52 | 998 | |
| other | Fall | Injury, poisoning and procedural complications | NSAID | 46 | 996 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Tanezumab 2.5 mg | 131 | 1,002 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Tanezumab 5 mg | 160 | 998 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | NSAID | 117 | 996 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Tanezumab 2.5 mg | 34 | 1,002 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Tanezumab 5 mg | 55 | 998 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | NSAID | 34 | 996 | |
| other | Headache | Nervous system disorders | Tanezumab 2.5 mg | 56 | 1,002 | |
| other | Headache | Nervous system disorders | Tanezumab 5 mg | 45 | 998 | |
| other | Headache | Nervous system disorders | NSAID | 25 | 996 | |
| serious | Anaemia | Blood and lymphatic system disorders | Tanezumab 2.5 mg | 0 | 1,002 | |
| serious | Anaemia | Blood and lymphatic system disorders | Tanezumab 5 mg | 0 | 998 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02528188/events